VP-16可能是目前单一用于治疗小细胞肺癌(SCCL)最有效的药物。在二期临床试验中,用于未接受过化疗的病人,有效率为20～65%,平均为43%。然而对于曾治疗过的病人疗效很低。本文介绍54例诱导化疗无效或完全缓解后3个月内复发的SCCL,单用VP_(?)和VP(?)与PDD 联合化 VP-16 may be currently the single most effective drug for the treatment of small cell lung cancer (SCCL). In phase II clinical trials, the effective rate was 20 to 65% for patients who had not received chemotherapy, with an average of 43%. However, the efficacy of the treatment of patients is very low. This article describes 54 cases of relapsed SCCL within 3 months after induction chemotherapy failure or complete remission, and the combination of VP_(?) and VP(?) with PDD alone.